DOI QR코드

DOI QR Code

Bioequivalence of Boryung Torsemide Tablet to Torem Tablet (Torasemide 10 mg) by High Performance Liquid Chromatography/UV Detector

  • Cho, Hea-Young (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University, Clinical Trial Center, Chonnam National University Hospital) ;
  • Kang, Hyun-Ah (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University, Clinical Trial Center, Chonnam National University Hospital) ;
  • Park, Chan-Ho (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University, Clinical Trial Center, Chonnam National University Hospital) ;
  • Kim, Se-Mi (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University, Clinical Trial Center, Chonnam National University Hospital) ;
  • Kim, Dong-Ho (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University, Clinical Trial Center, Chonnam National University Hospital) ;
  • Park, Sun-Ae (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University, Clinical Trial Center, Chonnam National University Hospital) ;
  • Kim, Kyung-Ran (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University, Clinical Trial Center, Chonnam National University Hospital) ;
  • Hur, Hyeon (Department of Biology, Dongguk University) ;
  • Lee, Yong-Bok (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University, Clinical Trial Center, Chonnam National University Hospital)
  • Published : 2005.10.20

Abstract

The purpose of the present study was to evaluate the bioequivalence of two torasemide tablets, Torem tablet (Roche Korea Co., Ltd., Korea, reference drug) and Boryung Torsemide tablet (Boryung Pharmaceutical Co., Ltd., Korea, test drug), according to the guidelines of Korea Food and Drug Administration (KFDA). After adding an internal standard (furosemide) to human serum, serum samples were extracted using 5 mL of ethyl acetate. Compounds were analyzed by reverse-phase HPLC method with UV detection. This method showed linear response over the concentration range of 0.05 ug/mL with correlation coefficient of 0.999. The lower limit of quantitation using 0.5 mL of serum was 0.05 ug/mL which was sensitive enough for pharmacokinetic studies. Twenty-eight healthy male Korean volunteers received each medicine at the torasemide dose of 20 mg in a $2{\times}2$ crossover study. There was a one-week washout period between the doses. Serum concentrations of torasemide were monitored by an HPLC-UV for over a period of 12 hr after the administration. $AUC_{t}$(the area under the serum concentration-time curve from time zero to 12 hr) was calculated by the linear trapezoidal rule method. $C_{max}$ (maximum serum drug concentration) and $T_{max}$ (time to reach $C_{max}$) were compiled from the serum concentration-time data. Analysis of variance was carried out using logarithmically transformed $AUC_{t}$ and $C_{max}$. No significant sequence effect was found for all of the bioavailability parameters indicating that the crossover design was properly performed. The 90% confidence intervals of the $AUC_{t}$ ratio and the $C_{max}$ ratio for Boryung Torsemide/Torem were log 0.97-10g 1.03 and log 0.93log 1.12, respectively. These values were within the acceptable bioequivalence intervals of log 0.80-log 1.25. Thus, the criteria of the KFDA guidelines for the bioequivalence was satisfied, indicating Boryung Torsemide tablet and Torem tablet are bioequivalent.

Keywords

References

  1. H. Knauf and E. Mutschler, Clinical pharmacokinetics and pharmacodynamics of torasemide, Clin. Pharmacokinet., 34(1), 1-24 (1998) https://doi.org/10.2165/00003088-199834010-00001
  2. H.P. Rang, M.M. Dale, J.M. Rtiter and P.K. Moore, Pharmacology, 5rd, ed., Churchill Livingstone, pp. 362 (2003)
  3. The Martindale, 32rd, ed., Pharmaceutical Press, pp. 956 (1999)
  4. G. Neugebauer, E. Besenfeledr, E.V. Mollendorff Pharmacokinetics and metabolism of torasemide in man, Arzneimittelforschung., 38(1A), 164-166 (1988)
  5. M. Lesne, F. Clerckx-Braun, P. Duhoux and C. van Ypersele de Strihou, Pharmacokinetic study of torasemide in humans: an overview of its diuretic effect, Int. J. Clin. Pharmacol. Ther. Toxicol., 20(8), 382-387 (1982)
  6. M. B.Barroso, R.M. Alonso and R.M. Jimenez, Simultaneous determination of torasemide and its major metabbolite M5 in human urine by high-performance liquid chromatography-electrochemical detection, J. Chromatogr. Sci., 39(11), 491-496 (2001) https://doi.org/10.1093/chromsci/39.11.491
  7. Korea Food & Drug Administration Notification No. 2002-60, Standard Protocol of Bioequivalence Test (2002. 11. 22)
  8. Guidance for Industry-Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Adaministration, Center for Drug Evaluation and Research, Center for Verternary Medicine, May 2001, http://www.fda.gov/cder/guidance/index.htm
  9. Korea Food & Drug Administration, Guidance for Industry, Statistical Approaches to Establishing Bioequivalence, Bioequivalence Division, Pharmacology Department, National Institute of Toxicology Department, 2003, http://www.kfda.go.kr/